RSS feed

Publications (original articles or review articles) published in 2023 from OUS - Section for urological oncology

9 publications found

Gerdtsson A, Torisson G, Thor A, Grenabo Bergdahl A, Almås B, Håkansson U, Törnblom M, Negaard HFS, Glimelius I, Halvorsen D, Karlsdóttir Á, Haugnes HS, Larsen SM, Holmberg G, Wahlqvist R, Tandstad T, Cohn-Cedermark G, Ståhl O, Kjellman A (2023)
Validation of a prediction model for post-chemotherapy fibrosis in nonseminoma patients
BJU Int, 132 (3), 329-336
DOI 10.1111/bju.16040, PubMed 37129962

Lilleby W, Seierstad T, Inderberg EM, Hole KH (2023)
Impact of human telomerase reverse transcriptase peptide vaccine combined with androgen deprivation therapy and radiotherapy in de novo metastatic prostate cancer: Long-term clinical monitoring
Int J Cancer, 152 (10), 2166-2173
DOI 10.1002/ijc.34448, PubMed 36715014

Lindberg S, Grozman V, Karlsson K, Onjukka E, Lindbäck E, Jirf KA, Lax I, Wersäll P, Persson GF, Josipovic M, Khalil AA, Møller DS, Hoffmann L, Knap MM, Nyman J, Drugge N, Bergström P, Olofsson J, Rogg LV, Hagen RK, Frøland AS, Ramberg C, Kristiansen C, Jeppesen SS, Nielsen TB et al. (2023)
Expanded HILUS Trial: A Pooled Analysis of Risk Factors for Toxicity From Stereotactic Body Radiation Therapy of Central and Ultracentral Lung Tumors
Int J Radiat Oncol Biol Phys, 117 (5), 1222-1231
DOI 10.1016/j.ijrobp.2023.06.246, PubMed 37423292

Møller CT, Tafjord G, Blindheim A, Berge V, Fosså S, Andreassen BK (2023)
Initial management and survival of patients with primary metastatic bladder cancer before the immunotherapy era: a population-based study from Norway
Scand J Urol, 58, 101-108
DOI 10.2340/sju.v58.5923, PubMed 37953521

Ost P, Siva S, Brabrand S, Dirix P, Liefhooghe N, Otte FX, Gomez-Iturriaga A, Everaerts W, Shelan M, Conde-Moreno A, López Campos F, Papachristofilou A, Guckenberger M, Scorsetti M, Zapatero A, Villafranca Iturre AE, Eito C, Couñago F, Muto P, Van De Voorde L, Mach N, Bultijnck R, Fonteyne V, Moon D, Thon K et al. (2023)
PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial
Eur Urol Oncol (in press)
DOI 10.1016/j.euo.2023.09.007, PubMed 37821242

Robsahm TE, Tsuruda KM, Hektoen HH, Storås AH, Cook MB, Hurwitz LM, Langseth H (2023)
Applying recommended definition of aggressive prostate cancer: a validation study using high-quality data from the Cancer Registry of Norway
Acta Oncol, 62 (1), 8-14
DOI 10.1080/0284186X.2023.2175331, PubMed 36762472

Storås AH, Tsuruda K, Fosså SD, Andreassen BK (2023)
Time trends in systemic treatment for patients with metastatic prostate cancer: a national cohort study
Acta Oncol, 62 (12), 1716-1722
DOI 10.1080/0284186X.2023.2257876, PubMed 37725527

Thorsen L, Courneya KS, Steene-Johannessen J, Gran JM, Haugnes HS, Negaard HFS, Kiserud CE, Fosså SD (2023)
Association of physical activity with overall mortality among long-term testicular cancer survivors: A longitudinal study
Int J Cancer, 153 (8), 1512-1519
DOI 10.1002/ijc.34625, PubMed 37334652

Wedde TB, Smaastuen MC, Vatne K, Schulz-Jaavall MB, Fosså SD, Lilleby WL (2023)
External beam radiotherapy of prostate cancer with or without high dose-rate brachytherapy: the Norwegian experience with long-term urinary and bowel adverse effects
Scand J Urol, 58, 68-75
DOI 10.2340/sju.v58.9571, PubMed 37644904